Envafolimab, CAS 2102192-68-5

Product Description: Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors[1][2][3].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Papadopoulos KP, et al. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. Oncologist. 2021 Sep;26(9):e1514-e1525./[2]Akinleye A, et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019 Sep 5;12(1):92./[3]Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T, Zhou A. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017 Mar 7;3:17004.

CAS Number: 2102192-68-5

Molecular Weight: N/A

Compound Purity: 99.77

Research Area: Cancer

Solubility: H2O

Target: PD-1/PD-L1

• Artikelnummer: MEXHY-P99115-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99115-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK